Johnson & Johnson is committed to meeting patient needs in established and new markets around the world. With the expansion of our global commercial portfolio, we are introducing new therapies for people living with neuropsychiatric, neurodegenerative, and neurological autoantibody-driven diseases.
We have a global, integrated team of diverse and world-renowned talent and partners who bring therapeutic options to patients who need them most.
We recognize the importance of ensuring our medicines are globally available. Our market-access strategy is focused on delivering clinical and payor value through evidence generation, innovative payor partnerships, and private market options.
Beyond this, we actively pursue licensing, acquisitions, academic partnerships, and public-private partnership opportunities to advance knowledge, education, and innovation in both established and emerging markets.